UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
News|Articles|July 1, 2025
OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025
Author(s)OncLive Staff
Fact checked by: Kristi Rosa
Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.
Advertisement
Advertisement
Below is your guide to all the oncologic therapeutic options that were cleared by the FDA in June 2025. The roundup provides everything you need to know, right at your fingertips—all the topline data that supported the decisions and expert insights contextualizing what they mean for clinical practice.
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Advertisement
Advertisement